Access the full text.
Sign up today, get DeepDyve free for 14 days.
L. Wittkop, H. Günthard, F. Wolf, D. Dunn, A. Cozzi-Lepri, A. Luca, C. Kücherer, N. Obel, V. Wyl, B. Masquelier, C. Stephan, C. Torti, A. Antinori, Federico García, A. Judd, K. Porter, R. Thiébaut, H. Castro, A. Sighem, Céline Colin, J. Kjaer, J. Lundgren, R. Paredes, A. Pozniak, B. Clotet, A. Phillips, D. Pillay, G. Chêne (2011)
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study.The Lancet. Infectious diseases, 11 5
W. Bannister, A. Cozzi-Lepri, B. Clotet, A. Mocroft, J. Kjær, P. Reiss, V. Wyl, A. Lazzarin, C. Katlama, A. Phillips, L. Ruíz, J. Lundgren (2008)
Transmitted Drug Resistant HIV-1 and Association With Virologic and CD4 Cell Count Response to Combination Antiretroviral Therapy in the EuroSIDA StudyJAIDS Journal of Acquired Immune Deficiency Syndromes, 48
P. Palumbo, J. Lindsey, M. Hughes, M. Cotton, R. Bobat, T. Meyers, M. Bwakura-Dangarembizi, B. Chi, P. Musoke, P. Kamthunzi, W. Schimana, L. Purdue, S. Eshleman, E. Abrams, L. Millar, E. Petzold, L. Mofenson, P. Jean‐Philippe, A. Violari (2010)
Antiretroviral treatment for children with peripartum nevirapine exposure.The New England journal of medicine, 363 16
Sui‐Yuan Chang, W. Sheng, Chun‐Nan Lee, Hsin-Yun Sun, C. Kao, Shu-Fang Chang, Wen‐Chun Liu, Jr-Yuan Yang, W. Wong, C. Hung, Shan-Chwen Chang (2006)
Molecular epidemiology of HIV type 1 subtypes in Taiwan: outbreak of HIV type 1 CRF07_BC infection in intravenous drug users.AIDS research and human retroviruses, 22 11
R. Hamers, M. Siwale, C. Wallis, Moheb Labib, Robbert Hasselt, W. Stevens, R. Schuurman, A. Wensing, M. Vugt, T. Wit (2010)
HIV-1 Drug Resistance Mutations Are Present in Six Percent of Persons Initiating Antiretroviral Therapy in Lusaka, ZambiaJAIDS Journal of Acquired Immune Deficiency Syndromes, 55
S. Little, S. Holte, J. Routy, E. Daar, M. Markowitz, A. Collier, R. Koup, J. Mellors, E. Connick, B. Conway, M. Kilby, Lei Wang, J. Whitcomb, N. Hellmann, D. Richman (2002)
Antiretroviral-drug resistance among patients recently infected with HIV.The New England journal of medicine, 347 6
B. Larder, G. Darby, D. Richman (1989)
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.Science, 243 4899
Chin-Hui Yang, Shih-Yan Yang, Ming-Hui Shen, H. Kuo (2008)
The changing epidemiology of prevalent diagnosed HIV infections in Taiwan, 1984-2005.The International journal on drug policy, 19 4
V. Johnson, F. Brun-vezinet, B. Clotet, H. Günthard, D. Kuritzkes, D. Pillay, J. Schapiro, D. Richman (2010)
Update of the drug resistance mutations in HIV-1: December 2010.Topics in HIV medicine : a publication of the International AIDS Society, USA, 18 5
M. Jakobsen, M. Tolstrup, O. Søgaard, L. Jørgensen, P. Gorry, A. Laursen, L. Ostergaard (2010)
Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 50 4
R. Grant, F. Hecht, M. Warmerdam, Lea Liu, T. Liegler, C. Petropoulos, N. Hellmann, M. Chesney, M. Busch, J. Kahn (2002)
Time trends in primary HIV-1 drug resistance among recently infected persons.JAMA, 288 2
M. Thompson, J. Aberg, P. Cahn, J. Montaner, G. Rizzardini, A. Telenti, J. Gatell, H. Günthard, S. Hammer, M. Hirsch, D. Jacobsen, P. Reiss, D. Richman, P. Volberding, P. Yeni, R. Schooley (2008)
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.JAMA, 304 3
Spread programme (2008)
Transmission of drug-resistant HIV-1 in Europe remains limited to single classesAIDS, 22
C. Mendoza, C. Garrido, A. Corral, G. Ramírez-Olivencia, I. Jiménez-Nácher, N. Zahonero, J. González-Lahoz, V. Soriano (2007)
Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients.AIDS research and human retroviruses, 23 7
D. Pillay, K. Bhaskaran, S. Jurriaans, M. Prins, B. Masquelier, F. Dabis, R. Gifford, C. Nielsen, C. Pedersen, C. Balotta, G. Rezza, M. Ortíz, C. Mendoza, C. Kücherer, G. Poggensee, J. Gill, K. Porter (2006)
The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapyAIDS, 20
J. Fox, S. Dustan, M. Mcclure, J. Weber, S. Fidler (2006)
Transmitted drug‐resistant HIV‐1 in primary HIV‐1 infection; incidence, evolution and impact on response to antiretroviral therapyHIV Medicine, 7
Jonathan Li, R. Paredes, H. Ribaudo, E. Svarovskaia, K. Metzner, M. Kozal, K. Hullsiek, M. Balduin, M. Jakobsen, A. Geretti, R. Thiébaut, L. Ostergaard, B. Masquelier, Jeffrey Johnson, Michael Miller, D. Kuritzkes (2011)
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.JAMA, 305 13
Victoria Johnson, Françoise Brun-Vézinet, B. Clotet, H. Gunthard, D. Kuritzkes, Deenan Pillay, J. Schapiro, D. Richman (2008)
Update of the Drug Resistance Mutations in HIV-1.Topics in HIV medicine : a publication of the International AIDS Society, USA, 16 5
G. Godin, C. Gagné, H. Naccache (2003)
Validation of a self-reported questionnaire assessing adherence to antiretroviral medication.AIDS patient care and STDs, 17 7
(2010)
Clin Infect Dis
J. Vercauteren, K. Deforche, K. Theys, M. Debruyne, L. Duque, S. Peres, A. Carvalho, K. Mansinho, A. Vandamme, R. Camacho (2008)
The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001–2006) in PortugalRetrovirology, 5
P. Sax, Runa Islam, R. Walensky, E. Losina, M. Weinstein, S. Goldie, Sara N. Sadownik, K. Freedberg (2005)
Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 41 9
Colette Smith, S. Staszewski, C. Sabin, M. Nelson, B. Dauer, P. Gute, M. Johnson, A. Phillips, B. Gazzard (2004)
Use of Viral Load Measured After 4 Weeks of Highly Active Antiretroviral Therapy to Predict Virologic Outcome at 24 Weeks for HIV-1–Positive IndividualsJAIDS Journal of Acquired Immune Deficiency Syndromes, 37
B. Bartmeyer, C. Kuecherer, C. Houareau, J. Werning, K. Keeren, S. Somogyi, C. Kollan, H. Jessen, S. Dupke, O. Hamouda (2010)
Prevalence of Transmitted Drug Resistance and Impact of Transmitted Resistance on Treatment Success in the German HIV-1 Seroconverter CohortPLoS ONE, 5
G. Poggensee, C. Kücherer, J. Werning, S. Somogyi, B. Bieniek, S. Dupke, H. Jessen, O. Hamouda (2007)
Impact of transmission of drug‐resistant HIV on the course of infection and the treatment success. Data from the German HIV‐1 Seroconverter StudyHIV Medicine, 8
William Wheeler, Rebecca Ziebell, H. Zabina, D. Pieniążek, J. Prejean, Ulana Bodnar, Kristen Mahle, W. Heneine, Jeffrey Johnson, H. Hall (2010)
Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.–2006AIDS, 24
M. Chaix, L. Desquilbet, D. Descamps, D. Costagliola, C. Deveau, J. Galimand, C. Goujard, A. Signori-Schmuck, V. Schneider, C. Tamalet, I. Pellegrin, M. Wirden, B. Masquelier, F. Brun-vezinet, C. Rouzioux, L. Meyer (2007)
Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance NetworkAntiviral Therapy, 12
(2011)
13 Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services
M. Oette, R. Kaiser, M. Däumer, R. Petch, G. Fätkenheuer, H. Carls, J. Rockstroh, D. Schmalöer, J. Stechel, T. Feldt, H. Pfister, D. Häussinger (2006)
Primary HIV Drug Resistance and Efficacy of First-Line Antiretroviral Therapy Guided by Resistance TestingJAIDS Journal of Acquired Immune Deficiency Syndromes, 41
D. Frentz, C. Boucher, M. Assel, A. Luca, M. Fabbiani, F. Incardona, P. Libin, N. Manca, V. Müller, B. Nualláin, R. Paredes, M. Prosperi, E. Quiros-Roldan, L. Ruíz, P. Sloot, C. Torti, A. Vandamme, K. Laethem, M. Zazzi, D. Vijver (2010)
Comparison of HIV-1 Genotypic Resistance Test Interpretation Systems in Predicting Virological Outcomes Over TimePLoS ONE, 5
M. Zazzi, M. Prosperi, I. Vicenti, S. Giambenedetto, A. Callegaro, B. Bruzzone, F. Baldanti, A. Gonnelli, E. Boeri, Elisabetta Paolini, S. Rusconi, A. Giacometti, F. Maggiolo, S. Menzo, A. Luca (2009)
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.The Journal of antimicrobial chemotherapy, 64 3
D. Kuritzkes, C. Lalama, H. Ribaudo, M. Marcial, W. Meyer, C. Shikuma, V. Johnson, S. Fiscus, R. D’Aquila, B. Schackman, E. Acosta, R. Gulick (2008)
Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.The Journal of infectious diseases, 197 6
Sui‐Yuan Chang, Mao‐Yuan Chen, Chun‐Nan Lee, Hsin-Yun Sun, W. Ko, Shu-Fang Chang, K. Chang, S. Hsieh, W. Sheng, Wen‐Chun Liu, Cheng‐Hsin Wu, C. Kao, C. Hung, Shan-Chwen Chang (2008)
Trends of antiretroviral drug resistance in treatment-naive patients with human immunodeficiency virus type 1 infection in Taiwan.The Journal of antimicrobial chemotherapy, 61 3
V. Wyl, S. Yerly, J. Böni, P. Bürgisser, T. Klimkait, M. Battegay, H. Furrer, A. Telenti, B. Hirschel, P. Vernazza, E. Bernasconi, M. Rickenbach, L. Perrin, B. Ledergerber, H. Günthard (2007)
Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types.Archives of internal medicine, 167 16
(2006)
J Acquir Immune Defic Syndr
L. Bansi, A. Geretti, D. Dunn, T. Hill, H. Green, E. Fearnhill, B. Gazzard, M. Nelson, K. Porter, A. Phillips, C. Sabin (2009)
The Impact of Transmitted Drug-Resistance on Treatment Selection and Outcome of First-Line Highly Active Antiretroviral Therapy (HAART)JAIDS Journal of Acquired Immune Deficiency Syndromes, 53
A. Fauci, J. Bartlett, E. Goosby, M. Smith, H. Kaiser, S. Chang, Jean Anderson, R. Armstead, A. Baker, David Barr, S. Bozzette, S. Cox, M. Delaney, F. Gordin, W. Greaves, M. Harrington, J. Henning, M. Hirsch, J. Jacobs, R. Marlink, C. Maxwell, J. Mellors, D. Nash, S. Perryman, R. Schooley, R. Sherer, S. Spector, G. Torres, P. Volberding, B. Brady, E. Daniels, D. Feigal, M. Feinberg, H. Gayle, T. Graydon, J. Kaplan, A. Macher, R. Martin, H. Masur, L. Mofenson, J. Murray, J. O'Neill, L. Pérez, R. Riseberg, S. Shekar, S. Stanley, J. Whitescarver (1998)
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000HIV Clinical Trials, 1
(2011)
Surveillance of transmitted and acquired HIV drug resistance using WHO surveys in resource-limited settings Foundation for Retrovirology and Human Health
A. Shet, Leslie Berry, H. Mohri, S. Mehandru, Chris Chung, A. Kim, Patrick Jean-Pierre, Christine Hogan, V. Simon, D. Boden, M. Markowitz (2006)
Tracking the Prevalence of Transmitted Antiretroviral Drug-Resistant HIV-1: A Decade of ExperienceJAIDS Journal of Acquired Immune Deficiency Syndromes, 41
P. Cane, I. Chrystie, D. Dunn, B. Evans, A. Geretti, H. Green, A. Phillips, D. Pillay, K. Porter, A. Pozniak, C. Sabin, E. Smit, J. Weber, M. Zuckerman (2005)
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational studyBMJ : British Medical Journal, 331
J. McKinnell, J. Willig, A. Westfall, Christa Nevin, J. Allison, J. Raper, M. Mugavero, M. Saag (2010)
Antiretroviral prescribing patterns in treatment-naïve patients in the United States.AIDS patient care and STDs, 24 2
A. Lepri, V. Miller, A. Phillips, H. Rabenau, C. Sabin, S. Staszewski (2001)
The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4–8 viral loadAIDS, 15
ObjectivesTo determine the impact of transmitted drug resistance (TDR) of HIV-1 on treatment outcome in areas where routine testing for drug resistance mutations may not be available before combination antiretroviral therapy (cART) is initiated.MethodsGenotypic resistance assays were performed on HIV isolates from archived blood samples obtained from 1349 antiretroviral-naive HIV-1-infected patients in Taiwan from 2000 to 2010. Resistance mutations were interpreted with the use of the HIVdb program of the Stanford University HIV Drug Resistance Database. The genotypic sensitivity score (GSS) of the regimens prescribed was calculated. A matched case–control study was conducted to assess the impact of TDR on treatment outcomes.ResultsThe overall prevalence of TDR to any antiretroviral agent was 8.0%, declining from 12.3% in 2003–06 to 5.1% in 2007–10. In the matched case–control study, 31 patients with high- or intermediate-level resistance, 16 with low-level resistance and 89 controls were enrolled. Compared with regimens with GSS >2.5, initiation of regimens with GSS ≤2.5 was associated with a higher treatment failure rate (39.3% versus 15.7%, P = 0.02) and shorter time to treatment failure (log-rank P < 0.001). In patients receiving regimens with GSS ≤2.5, protease inhibitor-based regimens were less likely to result in treatment failure, compared with non-nucleoside reverse-transcriptase inhibitor-based regimens (hazard ratio 0.26, 95% CI 0.06–1.12, P = 0.07).ConclusionsIn Taiwan the prevalence of TDR of HIV-1 strains declined and stabilized between 2007 and 2010. Receipt of antiretroviral regimens with GSS ≤2.5 was associated with poorer treatment responses than regimens with GSS >2.5.
Journal of Antimicrobial Chemotherapy – Oxford University Press
Published: May 1, 2012
Keywords: genotypic resistance mutations highly active antiretroviral therapy HIV infection
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.